GSK wins priority status for new HIV drug in U.S

A GlaxoSmithKline logo is seen outside one of its buildings in west London, ahead of company resultsLONDON (Reuters) – U.S. regulators gave priority review status to an experimental GlaxoSmithKline drug for HIV/AIDS, which industry analysts view as a possible multibillion-dollar-a-year seller. The U.S. Food and Drug Administration awards certain drugs priority status when they have the potential to offer significant improvement over existing treatments. The agency is due to give its verdict on whether to approve dolutegravir by August 17, Britain's biggest drugmaker said on Friday. …



Sexual Health News Headlines – Yahoo! News